Investment Thesis
Enveric Biosciences faces severe operational distress evidenced by negative revenue (-303.00, -148.4% YoY decline) and persistent operating cash burn of -2.3M annually. While the company maintains exceptional liquidity with 4.9M cash and low leverage, this liquidity masks fundamental business failure requiring immediate operational turnaround or capital restructuring.
Strengths
- Exceptional liquidity position with 11.67x current ratio and 4.9M cash reserves (89% of total assets)
- Conservative capital structure with low leverage (0.15x debt/equity ratio) and manageable long-term debt of 740.3K
- Year-over-year improvement in losses (net income loss narrowing by 26.7% and diluted EPS improving by 84.1%)
Risks
- Negative revenue of -303.00 with -148.4% YoY deterioration indicates fundamental business failure, likely from refunds/returns exceeding sales
- Persistent negative operating cash flow of -2.3M annually combined with negative operating income of -1.6M demonstrates non-sustainable business model
- Cash runway of approximately 2+ years at current burn rate, insufficient for pharmaceutical sector requiring long R&D cycles and regulatory approvals
- Zero insider Form 4 filings in 90 days suggests lack of insider confidence in company direction
Key Metrics to Watch
- Revenue stabilization and return to positive sales figures
- Operating cash flow inflection point above zero
- Cash burn rate trajectory and time to cash depletion at current burn rate
Financial Metrics
Revenue
-303.0
Net Income
-1.6M
EPS (Diluted)
$-1.08
Free Cash Flow
-2.3M
Total Assets
5.5M
Cash
4.9M
Profitability Ratios
Gross Margin
-1,843,958.1%
Operating Margin
539,000.0%
Net Margin
539,100.0%
ROE
-32.3%
ROA
-29.6%
FCF Margin
746,540.9%
Balance Sheet & Liquidity
Current Ratio
11.67x
Quick Ratio
11.67x
Debt/Equity
0.15x
Debt/Assets
72.4%
Interest Coverage
-148,470.00x
Long-term Debt
740.3K
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-16T08:08:01.952390 |
Data as of: 2026-03-31 |
Powered by Claude AI